Andrew Berens Leerink Partners Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
14
Avg Return
Past Year
Past Year
95%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
85.7%
Neutral
14.3%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mega Cap
Over $200B
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Maintained
| $58 |
106%
upside
| 1 | +1.4% |
0
%
| 3 Mar ‘26 1 month ago |
|
|
|
Outperform
Upgraded
| $8 |
11%
upside
| 1 | +58% |
0
%
| 23 Jan ‘26 3 months ago |
|
|
|
Outperform
Initiated
| $46 |
86%
upside
| 1 | +20% |
0
%
| 7 Jan ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $40 |
58%
upside
| 2 | +14% |
0
%
| 26 Dec ‘25 4 months ago |
|
|
|
Outperform
Maintained
| $149 |
43%
upside
| 2 | +15% |
0
%
| 17 Nov ‘25 5 months ago |
|
|
|
Outperform
Maintained
| $50 |
36%
upside
| 2 | +119% |
0
%
| 10 Nov ‘25 5 months ago |
|
|
|
Outperform
Initiated
| $15 |
148%
upside
| 1 | -22% |
0
%
| 31 Oct ‘25 5 months ago |
|
|
|
Market Perform
Downgraded
| $97 |
8%
upside
| 1 | – |
–
| 6 Oct ‘25 6 months ago |
|
|
|
Outperform
Initiated
| $25 |
185%
upside
| 1 | -8.2% |
0
%
| 17 Sep ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $60 |
50%
downside
| 1 | +749% |
0
%
| 28 Jul ‘25 9 months ago |
|
|
|
Market Perform
Downgraded
| $9 |
14%
downside
| 1 | – |
–
| 2 Jun ‘25 10 months ago |
|